Differential expression of MET between primary and metastatic sites in clear cell Renal Cell Carcinomas (ccRCCs)
An alternative titration schedule of axitinib in metastatic renal cell carcinoma
Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients with metastatic renal cell carcinoma (mRCC)
Effect of everolimus on renal function in patients with tuberous sclerosis complex (TSC): Results from EXIST-1 and EXIST-2
Everolimus for renal angiomyolipoma associated with tuberous sclerosis complex (TSC): EXIST-2 long-term follow-up
Recurrence after surgery in non-metastatic RCC with thrombus; risk factors from a contemporary multicenter analysis
Trial in progress: phase 1b dose-finding study of axitinib plus pembrolizumab for first-line treatment of advanced renal cell carcinoma (RCC)
Extension of survival in patients with metastatic renal cell carcinoma (mRCC) treated with high dose interleukin-2 (HD IL-2) immunotherapy in the post 2006 targeted therapy era
Immune cell repertoire in patients with metastatic renal cell carcinoma: data from a prospective clinical trial
Whole-exome sequencing predicting two extreme phenotypes of response to VEGF-targeted therapies in metastatic clear cell renal cell carcinoma (mRCC)
Patient identification and eligibility insights in the synchronous mRCC population: an update from the ongoing ADAPT* phase 3 study experience
Effect of everolimus on renal angiomyolipoma in pediatric patients with tuberous sclerosis complex (TSC) being treated for subependymal giant cell astrocytoma (SEGA)
Phase I study of nivolumab in combination with ipilimumab (IPI) in metastatic renal cell carcinoma (mRCC)
A phase 3, randomized, open-label study of nivolumab combined with ipilimumab versus sunitinib monotherapy in subjects with previously untreated metastatic renal cell carcinoma
TRPM3 and miR-204 establish a regulatory circuit that controls oncogenic autophagy in clear cell renal cell carcinoma (ccRCC)
A critical analysis and validation of the renal cell carcinoma biomarker literature using the cancer genome atlas (TCGA)
Risk factors and a model to predict toxicity-related treatment discontinuation in patients with metastatic renal cell carcinoma (mRCC) treated with vascular endothelial growth factor (VEGF)-targeted therapy: results from the international metastatic RCC database consortium (IMDC)
A minimally invasive, lentiviral based method for the rapid and sustained genetic manipulation of mouse tubular epithelial cells
Immune correlates and long-term follow-up of a Phase Ia study of MPDL3280A, an engineered PD-L1 antibody, in patients with metastatic renal cell carcinoma (mRCC)
Patients with PD-L1 expression by IHC 1/2/3 demonstrated evidence of increased activity. Durable responses were observed in mRCC patients, warranting further study Randomized, dose-ranging phase II trial of nivolumab for metastatic renal cell carcinoma (mRCC)
Bacteriomic profiling reveals potential etiology for vascular endothelial growth factor-tyrosine kinase inhibitor (VEGF-TKI)-related diarrhea in patients with metastatic renal cell carcinoma (mRCC)
Treatment patterns in metastatic renal cell carcinoma in the US: a retrospective chart review
Cost analysis of an initial observation approach in metastatic renal cell carcinoma from a prospective study
Patient and tumor characteristics predict indeterminate renal mass biopsy findings
Clinical and radiographic predictors of the need for resection of the inferior vena cava during nephrectomy for patients with renal cell carcinoma and caval tumor thrombus
Concommittant surgery for hepatic involvement at the time of nephrectomy for renal cell carcinoma: a matched cohort study
The increasing complexity of tumor thrombi in renal cell carcinoma: 39 years of experience
AUA and NCCN surveillance guidelines for RCC: do they effectively capture recurrences following nephrectomy?
FGFR1 overexpression could impact on efficacy of FGFR-targeted therapy in renal cell carcinoma
DART Study: A phase 2 randomized trial of dalantercept plus axitinib versus placebo plus axitinib in advanced renal cell carcinoma (RCC): Results from the part 1 dose escalation cohorts.
A composite score of 5 circulating biomarkers predicts benefit from everolimus: Results from 442 patients (pts) randomized on RECORD-3
Tumor purity and immune cell infiltration as a prognostic risk predictor for clear cell renal cell carcinoma
Abstract: a review of interventional clinical trials in renal cell carcinoma (RCC): a status report from the ClinicalTrials.gov website